Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Cancer Research Communications|March 27, 2023
Mechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic LeukemiaThibaud Derippe, Sylvain Fouliard, Ibtissam Marchiq, et al.
Plos One|December 27, 2024
The combined use of scRNA-seq and network propagation highlights key features of pan-cancer Tumor-Infiltrating T cellsAdèle Mangelinck, Elodie Molitor, Ibtissam Marchiq, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 21, 2011
CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumorsRenaud Le Floch, Johanna Chiche, Ibtissam Marchiq, et al.
Cancer Research Communications|March 27, 2023
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic LeukemiaSandra Dupouy, Ibtissam Marchiq, Thibaud Derippe, et al.
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?Sonia Guedan, Maik Luu, Delphine Ammar, et al.
Lancet (London, England)|December 14, 2020
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studiesReuben Benjamin, Charlotte Graham, Deborah Yallop, et al.
Journal for Immunotherapy of Cancer|May 16, 2022
Time to evolve: predicting engineered T cell-associated toxicity with next-generation modelsEmmanuel Donnadieu, Maik Luu, Miriam Alb, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|October 28, 2014
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortiumErik O Pettersen, Peter Ebbesen, Roben G Gieling, et al.
Pageof 2